Technology
Core annular flow surrounds the viscous drug product with a thin, low-viscosity fluid that shields it from the needle wall. Because the drug never contacts the wall — where the shear is highest — the force needed to inject it is set by the low-viscosity fluid rather than the drug's own viscosity.
This breaks the conventional relationship between viscosity and injection force. Force stays low and nearly flat even at extreme concentrations, enabling low-force delivery of ultra-high-concentration formulations that a standard syringe could never push through a fine needle.
The future of healthcare without viscosity constraints
High-dose IV to SC transition
Turn hours-long hospital infusions into 10-second injections at home.
Dual-drug administration
Co-deliver two formulations in a single injection.
Extend dosing intervals
Unlock higher doses and drug conjugation to reduce injection frequency.
Prioritize patient comfort
Reduce injection volume and time without compromising complexity.
Expand the discovery funnel
Carry candidates forward that viscosity would otherwise have ruled out.
The CO-AXL Hub Platform
The CO-AXL hub is a universal single-component device that adapts any primary container for user-friendly administration.
Inject the uninjectable
Deliver formulations up to 400 mg/mL and over 1,000 cP — including non-Newtonian gels and suspensions.
No change to container or drug
No particle reformulation, and no new compounds — with the drug buffer as the saline solution.
One platform for an entire pipeline
One device across your entire portfolio — any molecule, volume, indication, and route of administration.
